arGEN-X N.V. today announced that it has initiated a clinical efficacy evaluation of ARGX-110, its investigational anti-CD70 therapeutic antibody, in patients with relapsed/refractory CD70-positive T-cell lymphomas.
arGEN-X N.V. today announced that it has initiated a clinical efficacy evaluation of ARGX-110, its investigational anti-CD70 therapeutic antibody, in patients with relapsed/refractory CD70-positive T-cell lymphomas.